Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 775 of 808 entries
View as:

Exercise for Tumor Suppressive Impact in Black Men With Prostate Cancer on Active Surveillance: The REMOVE Trial

Phase: N/A Priority: Normal
NCT ID: NCT05918263 Org: User:
Start: 01/01/24 End: 03/31/27 Due: 03/31/28

A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT02251548 Org: User:
Start: 10/31/14 End: 01/31/27 Due: 01/31/28

Qigong For PPSP In Breast Cancer Pain In Breast Cancer Survivors

Phase: N/A Priority: Normal
NCT ID: NCT02848989 Org: User:
Start: 04/04/17 End: 02/03/23 Due: 02/03/24

Study of Gemcitabine and Vinorelbine in Soft Tissue Sarcomas

Phase: N/A Priority: Normal
NCT ID: NCT00134641 Org: User:
Start: 02/28/03 End: 06/30/07 Due: 06/30/08

Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00165464 Org: User:
Start: 08/31/01 End: 04/30/09 Due: 04/30/10

Lenalidomide for Adult Histiocyte Disorders

Phase: N/A Priority: Normal
NCT ID: NCT02523040 Org: User:
Start: 08/31/15 End: 08/31/25 Due: 08/31/26

Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy.

Phase: N/A Priority: Normal
NCT ID: NCT03137537 Org: User:
Start: 02/27/18 End: 11/18/20 Due: 11/18/21

Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Military Population: The Sentinel Study

Phase: N/A Priority: Normal
NCT ID: NCT06523868 Org: User:
Start: 03/31/25 End: 09/30/28 Due: 09/30/29

A Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02133625 Org: User:
Start: 08/31/11 End: 01/31/16 Due: 01/31/17

Cabozantinib for Metastatic Triple Negative BrCa

Phase: N/A Priority: Normal
NCT ID: NCT01738438 Org: User:
Start: 02/28/13 End: 05/31/15 Due: 05/31/16

Gemcitabine, 5-Fluorouracil, and Radiation Therapy in the Treatment of Non-Metastatic Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00251355 Org: User:
Start: 01/31/98 End: 08/31/08 Due: 08/31/09

CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia

Phase: N/A Priority: Normal
NCT ID: NCT00142168 Org: User:
Start: 09/30/04 End: 04/30/08 Due: 04/30/09

Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC)

Phase: N/A Priority: Normal
NCT ID: NCT05629065 Org: User:
Start: 11/28/22 End: 07/31/25 Due: 07/31/26

Two Doses of Conjugated Estrogen (Premarin) in Patients With Androgen-Independent Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00134654 Org: User:
Start: 03/31/03 End: 06/30/11 Due: 06/30/12

Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00251368 Org: User:
Start: 01/31/95 End: 09/30/07 Due: 09/30/08

OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas

Phase: N/A Priority: Normal
NCT ID: NCT01600807 Org: User:
Start: - End: - Due: -

A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03316586 Org: User:
Start: 11/30/17 End: 08/30/19 Due: 08/30/20

Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Phase: N/A Priority: Normal
NCT ID: NCT03485547 Org: User:
Start: 08/23/18 End: 02/17/26 Due: 02/17/27

Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6

Phase: N/A Priority: Normal
NCT ID: NCT03310879 Org: User:
Start: 11/21/17 End: 04/30/26 Due: 04/30/27

Effect of Surefire Infusion Device on Tumor Response to Regional Intra-arterial Therapy for Primary Liver Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT02853500 Org: User:
Start: 07/31/16 End: 02/03/25 Due: 02/03/26

A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT02903381 Org: User:
Start: 10/20/16 End: 09/16/21 Due: 09/16/22

VB-111 in Surgically Accessible Recurrent/Progressive GBM

Phase: N/A Priority: Normal
NCT ID: NCT04406272 Org: User:
Start: 08/01/20 End: 08/01/24 Due: 08/01/25

Patient-Centered Surgical Prehabilitation

Phase: N/A Priority: Normal
NCT ID: NCT05715684 Org: User:
Start: 03/01/23 End: 12/25/27 Due: 12/25/28

The COMPASSION Study

Phase: N/A Priority: Normal
NCT ID: NCT06507930 Org: User:
Start: 09/01/24 End: 03/01/26 Due: 03/01/27

The Myelodysplasia Transplantation-Associated Outcomes (MDS-TAO) Study

Phase: N/A Priority: Normal
NCT ID: NCT02390414 Org: User:
Start: 05/31/11 End: 09/30/20 Due: 09/30/21